IDbyDNA Information
Contact top employees from
IDbyDNA
Summary
IDbyDNA is a private company that has been in the industry for 11 years. The company currently specializes in the Biotechnology, Biotechnology, Medical Research & Laboratories areas. The position of the CEO is occupied by Neil Gunn. Its headquarters is located at Salt Lake City, Utah, USA. The number of employees ranges from 25 to 100. The annual revenue of IDbyDNA varies between 5.0M and 25M. Total funding of the company - $30M. To connect with IDbyDNA employee register on SignalHire.
Organization Website | idbydna.com |
Social Links |  |
Phone Number | 833-432-9362 |
Industries | |
Headquarters Location | 675 Arapeen Drive, Salt Lake City, UT, 84108 US |
Employees Size | 100-200 employees |
SIC Code | 2836, 8731 |
DMA Code | Salt Lake City Metropolitan Area |
Founded | 2014 |
Estimated Annual Revenue | $5.0M - 25M |
Operating Status | Independent Company |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2008 | Privately Held | 25 - 100 | 7.5M | $22.5M | |
| 2015 | Privately Held | 1 - 25 | 1.6M | $9.9M | |
| 2008 | Privately Held | 25 - 100 | 6M | $9.4M | |
| 2009 | Privately Held | 25 - 100 | 12M | $68.7M |
Employees Turnover 3 quarter 2025
Length of Employment
Employee tenure at IDbyDNA shows a diverse range of experience levels:
26% for 3–4 years47% for 5–7 years21% for 8–10 years5% have over 11 years of service at IDbyDNAContact top employees from
IDbyDNA
Jeffrey Field
Chief Commercial Officer
Lyna Garcia
Senior Executive Client Servicing
Yuying Mei
Associate Director
Similar Companies
FAQ
IDbyDNA operates in the Biotech industries. More details can be found on the official website: idbydna.com.
The headquarters of IDbyDNA are located in Salt Lake City, United States.
The current CEO of IDbyDNA is Neil Gunn
You can contact IDbyDNA by phone at 833-432-9362.
IDbyDNA currently employs 100-200 people.
IDbyDNA's revenue is approximately 14.3M.
Well-known competitors of IDbyDNA include First Light Diagnostics, Phase Genomics, Cosmos-Hub and Second Genome Inc..
